|
|
|
|
|
| Taylor, S. T.; Ellison, J. A.; Franka, R.; Marissen, W. E.; Rupprecht, C.. |
| Rabies is an acute progressive encephalitis responsible for over 55,000 human fatalities each year. This zoonosis is preventable, if prompt medical intervention includes wound care and both active and passive immunization. Approximately 10 million people receive rabies post-exposure prophylaxis (PEP) annually. The World Health Organization recommends the administration of human and/or equine derived antirabies immune globulin (HRIG and ERIG) as well as cell culture vaccine for modern PEP in humans. However, in many developing regions where canine rabies is enzootic, alternative solutions for passive immunization are necessary due to the cost prohibitive, limited supply of HRIG and ERIG. Such disparities have prompted the development of anti-RABV monoclonal... |
| Tipo: Info:eu-repo/semantics/article |
|
| Ano: 2013 |
URL: http://www.revistamvez-crmvsp.com.br/index.php/recmvz/article/view/246 |
| |
|
|
| Marissen, W. E.; Niezgoda, M.; Ellison, J.; Franka, R.; Kuzmina, N.; Kusmin, I.; Taylor, T.; Rupprecht, C.. |
| The currently recommended prophylaxis for individuals exposed to rabies virus is the combined administration of rabies vaccine and rabies immune globulin (RIG). However, limited supply hampers the availability of RIG, particularly in enzootic areas. To circumvent the global RIG limitation we aimed to develop a human monoclonal antibody combination, CL184, for rabies post-exposure prophylaxis (PEP) that would replace the plasma origin RIG. CL184 consists of two human IgG1 mAbs, CR57 and CR4098, which are directed against non-overlapping rabies virus (RV) glycoprotein epitopes. Previously, we have shown that the in vitro breadth of neutralization of CL184 against a large panel of street RV of various animal origins as well as in vivo protection by CL184 in a... |
| Tipo: Info:eu-repo/semantics/article |
|
| Ano: 2013 |
URL: http://www.revistamvez-crmvsp.com.br/index.php/recmvz/article/view/249 |
| |
|
|
|
